China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into a memorandum of understanding (MOU) with Japan-based startup Toregem BioPharma. The collaboration focuses on the development of Toregem’s TRG035, an anti-USAG-1 monoclonal antibody being developed to treat congenital tooth loss. This partnership aims to leverage WuXi Biologics’ comprehensive end-to-end services to advance the R&D of TRG035.
Agreement Details
Under the agreement, Toregem will utilize WuXi Biologics’ services for cell line development, cell line library building, analytical method development, cell culture process development, stock solutions, preparation production, and biological activity method development. These services are designed to support the efficient and effective development of TRG035.
Toregem BioPharma: Company Profile and Technology
Toregem BioPharma is a biotech startup incubated by Kyoto University, focusing on antibodies targeting tooth regeneration. The company’s lead candidate, TRG035, targets USAG-1, a bifunctional protein that antagonizes BMP and Wnt, two critical signal molecules necessary for tooth development. Animal experiments have demonstrated that the BMP/Wnt signal pathway is essential for determining the number of teeth, and a single dose of the drug can induce the growth of a complete tooth.
Future Outlook
The partnership between WuXi Biologics and Toregem BioPharma highlights the potential of combining advanced biologics development services with innovative therapeutic targets. By working together, the companies aim to accelerate the development of TRG035 and bring a novel treatment option for congenital tooth loss closer to patients.-Fineline Info & Tech
